In a landmark shift for global public health, AbbVie’s direct-acting antiviral (DAA) therapy, Maviret (glecaprevir/pibrentasvir)—marketed as Mavyret in the United States—has secured approval from the European Commission for the treatment of both acute and chronic hepatitis C virus (HCV) infection. This regulatory milestone effectively eliminates the clinical requirement to wait for an infection to become "chronic" before intervention, clearing the path for immediate treatment upon diagnosis.
For decades, the "wait-and-see" approach dominated the medical landscape. Physicians often delayed treatment to determine if a patient would spontaneously clear the virus, or to adhere to insurance and regulatory hurdles that defined the disease by its duration. By expanding the indication for Maviret, the medical community is moving toward a proactive model where the diagnosis of HCV is the only prerequisite for initiating a curative regimen.
The Evolution of HCV Care: From Chronicity to Immediate Action
The hepatitis C virus has historically been categorized into two phases: acute (the initial six months post-infection) and chronic (persistent infection beyond six months). Clinical guidelines from 2020 had already begun to suggest that prompt treatment of acute HCV was beneficial, yet the disconnect between clinical recommendation and regulatory approval created a "limbo" for patients.
Mudra Kapoor, Vice President of Neuroscience, Eyecare, Specialty, and VIO Medical Affairs + Health Impact at AbbVie, explains the frustration inherent in the old system. "We no longer have to go through additional steps to check for chronicity or worry about how far back the patient contracted the infection," Kapoor said in an interview. "Routine practice needs to get to a point where the minute you diagnose someone as positive for HCV, you treat them. That is not where we are, but it is where we need to go."
The shift is not merely administrative; it is a fundamental change in the philosophy of infectious disease control. By treating patients immediately, healthcare providers can prevent the further transmission of the virus, effectively turning a treatment for the individual into a preventative measure for the community.
Chronology of a Medical Breakthrough
The path to this approval has been paved by decades of scientific advancement and evolving policy.
The Era of Uncertainty (Pre-2010s)
Historically, HCV treatment was a grueling, low-efficacy process. Patients were often subjected to interferon-based therapies that required injections three times a week for months. These treatments were associated with significant systemic side effects, low success rates, and heavy logistical burdens. Given this high-risk, low-reward profile, the medical community’s hesitation to treat acute cases—which carry a natural clearance rate of approximately 26%—was, at the time, clinically defensible.
The DAA Revolution (2017)
The landscape shifted dramatically in 2017 with the approval of Maviret. As a fixed-dose combination of glecaprevir (a protease inhibitor) and pibrentasvir (an NS5A inhibitor), the drug provided a high-barrier-to-resistance solution. By blocking the enzymes necessary for viral polyprotein cleavage and RNA replication, Maviret transformed HCV from a lifelong, potentially life-threatening condition into a manageable, curable, short-term infection.
Regulatory Alignment (2026)
Following the success of the Phase 3 M20-350 trial, which demonstrated a 96.2% sustained virologic response (SVR) 12 weeks after an eight-week treatment course, European regulators finally aligned the approved usage of Maviret with modern clinical realities. This decision acknowledges that with modern, safe, and highly effective therapies, the "wait-and-see" approach is no longer a prudent risk-management strategy.
Supporting Clinical Data: The M20-350 Trial
The regulatory expansion was bolstered by the robust data from the M20-350 clinical trial. In this study, investigators evaluated the efficacy and safety of the eight-week, once-daily regimen of glecaprevir/pibrentasvir in patients with acute HCV.
The results were compelling: 96.2% of participants achieved SVR12—the gold standard for a "cure" in HCV research. The mechanism of action is precise; glecaprevir disrupts the virus’s ability to assemble mature viral proteins, while pibrentasvir serves as a potent inhibitor of the protein essential for the assembly of new viral particles.
By achieving such high clearance rates with a short, eight-week course, the data provided the evidence needed to convince regulators that the benefits of immediate intervention—namely, the immediate cessation of viral replication and the reduction of the transmission window—far outweigh the risks associated with treating patients who might have otherwise cleared the virus on their own.
Official Responses and the "Ecosystem" Approach
AbbVie’s leadership emphasizes that while the drug is a scientific marvel, the fight against hepatitis C is a social and political challenge. Mudra Kapoor stresses that the drug itself is only one piece of a much larger puzzle.
"Changing the standard of care takes more than approving a treatment or getting it to market," Kapoor noted. "There’s a whole ecosystem that needs to work together to eliminate the disease."
This "ecosystem" includes pricing models and access initiatives. In 2019, Washington state famously partnered with AbbVie in a "Netflix-style" subscription model, allowing the state to provide unlimited access to Maviret for a flat fee. This was designed to eliminate the cost-containment barriers that often lead to rationing of care.
However, the path has not been without criticism. In 2021, the Médecins Sans Frontières (MSF) Access Campaign issued an open letter to AbbVie, arguing that despite voluntary licensing agreements with the Medicines Patent Pool—which were intended to facilitate access in 99 low- and middle-income countries—the price and availability of the drug remained a barrier for many of the world’s most vulnerable populations.
Case Study: The Lithuanian Model
The potential for success is best exemplified by the progress in Lithuania. In 2022, Lithuanian health authorities launched a national HCV screening program, bolstered by a financial incentive structure for general practitioners to conduct antibody testing.
The program was highly successful, testing more than 75% of the 1945–1994 birth cohort within 34 months. The result was a threefold increase in the number of patients receiving treatment. Yet, researchers noted that even with this success, Lithuania remains behind the WHO’s 2030 elimination targets. The lesson, according to public health experts, is that screening is not enough; one must also remove "fibrosis-stage" restrictions—rules that only allow the sickest patients to receive treatment—to truly achieve elimination.
Implications for Global Health
The approval of Maviret for acute HCV is a clarion call for healthcare systems globally. The implication is clear: the technology to eliminate hepatitis C exists, but the barriers to its application are now largely bureaucratic and socioeconomic.
1. Re-evaluating Diagnostic Urgency
The medical community must now pivot toward "test-and-treat" models. In this framework, the diagnosis of HCV should trigger an immediate referral to treatment, rather than a referral for further monitoring or a "watchful waiting" period.
2. Addressing the Socioeconomic Benefits
Treating acute HCV is not just an individual health benefit; it is a public health necessity. By curing an infected individual, the risk of onward transmission is permanently eliminated. When scaled across a population, this approach drastically reduces the total viral burden and the long-term costs associated with managing chronic liver disease, cirrhosis, and liver cancer.
3. Strengthening Public-Private Partnerships
As Kapoor highlighted, no single company can achieve the WHO’s 2030 goals. The success of the Lithuanian model and the Washington state subscription plan demonstrates that success requires the alignment of policymakers, payers, and pharmaceutical manufacturers.
Conclusion: The Path Forward
The "wait-and-see" era for hepatitis C is effectively over. With the approval of Maviret for acute infection, the medical field has the tools, the clinical evidence, and now the regulatory mandate to act immediately upon diagnosis.
However, the final challenge remains: the will to implement these changes across diverse global healthcare systems. As AbbVie and other stakeholders look toward 2030, the focus must shift from the development of new molecules to the dismantling of the systemic barriers that keep patients from accessing the cures that already exist.
"That future is possible," says Kapoor, "and AbbVie is completely committed to it. But we need policymakers to take action, we need payers to take action, and we need everyone to actually want to eliminate HCV."
The science has provided the solution; the rest of the world must now provide the infrastructure. The transition from managing a chronic pandemic to eliminating a curable disease is no longer a matter of ‘if,’ but a matter of ‘how fast.’
About the Author
